OBJECTIVES: Although the incidence of measles has decreased globally since the introduction of regular vaccination, its frequency has increased again in recent years. The study is focused on data from the Olomouc Region in the Czech Republic analyzed in four laboratories. The obtained results were compared with already published data. METHODS: The data were provided by individual laboratories in an anonymized form-age at the time of the examination, sex, and result of test. Samples were collected between June 2018 and September 2019 and evaluated on the scale positive-borderline-negative. RESULTS: A total of 7962 sera samples were evaluated using three different methods-two types of ELISA tests and CLIA. Positive result was issued in a total of 62.6 percent of samples, but the results of individual laboratories varied widely from 55.5 to 70.8 percent. However, the same trend with the highest levels of antibodies in people born before beginning of vaccination was observed. CONCLUSIONS: Data show significantly different results depending on the individual laboratories and the detection kits used. The underestimation of the proportion of positive results can cause problems in selecting individuals for revaccination with a live vaccine, which may fail in weakly positive individuals.

AGEL Laboratories a s 703 84 Ostrava Vítkovice Czech Republic

Department of Immunology Faculty of Medicine and Dentistry Palacky University Olomouc 775 15 Olomouc Czech Republic

Department of Microbiology University Hospital Olomouc and Faculty of Medicine and Dentistry Palacky University Olomouc 775 15 Olomouc Czech Republic

Department of Surgery University of Alabama at Birmingham Birmingham AL 35294 USA

Mikrochem Laboratories a s 779 00 Olomouc Czech Republic

Science and Research Centre Faculty of Health Sciences Palacky University Olomouc Hněvotínská 3 775 15 Olomouc Czech Republic

Šumperk Hospital 787 01 Šumperk Czech Republic

Zobrazit více v PubMed

Nambulli S., Sharp C.R., Acciardo A.S., Drexler J.F., Duprex W.P. Mapping the evolutionary trajectories of morbilliviruses: What, where and whither. Curr. Opin. Virol. 2016;16:95–105. doi: 10.1016/j.coviro.2016.01.019. PubMed DOI PMC

Moss W.J. Measles. Lancet. 2017;390:2490–2502. doi: 10.1016/S0140-6736(17)31463-0. PubMed DOI

Guerra F.M., Bolotin S., Lim G., Heffernan J., Deeks S.L., Li Y., Crowcroft N.S. The basic reproduction number (R0) of measles: A systematic review. Lancet Infect. Dis. 2017;17:e420–e428. doi: 10.1016/S1473-3099(17)30307-9. PubMed DOI

Remington P.L., Hall W.N., Davis I.H., Herald A., Gunn R.A. Airborne Transmission of Measles in a Physician’s Office. J. Am. Med. Assoc. 1985;253:1574–1577. doi: 10.1001/jama.1985.03350350068022. PubMed DOI

Lindberg C., Lanzi M., Lindberg K. MEASLES: Still a Significant Health Treat. MCN Am. J. Matern. Child Nurs. 2015;40:298–305. doi: 10.1097/NMC.0000000000000162. PubMed DOI

Leung A.K.C., Hon K.L., Leong K.F., Sergi C.M. Measles: A disease often forgotten but not gone. Hong Kong Med. J. 2018;24:512–520. doi: 10.12809/hkmj187470. PubMed DOI

Gutierrez J., Issacson R.S., Koppel B.S. Subacute sclerosing panencephalitis: An update. Dev. Med. Child Neurol. 2010;52:901–907. doi: 10.1111/j.1469-8749.2010.03717.x. PubMed DOI

Enders J.F., Peebles T.C. Propagation in Tissue Cultures of Cytopathogenic Agents from Patients with Measles. Proc. Soc. Exp. Biol. Med. 1954;86:277–286. doi: 10.3181/00379727-86-21073. PubMed DOI

Griffin D.E. Measles Vaccine. Viral Immunol. 2018;31:86–95. doi: 10.1089/vim.2017.0143. PubMed DOI PMC

Katz S.L., Enders J.F., Holloway A. the Development and Evaluation of an attenuated measles virus vaccine. Am. J. Public Health Nations Health. 1967;52:5–10. doi: 10.2105/AJPH.52.Suppl_2.5. PubMed DOI PMC

Plotkin S.A., Orenstein W.A., Offit P.A. Plotkin’s Vaccines. Elsevier; Amsterdam, The Netherlands: 2018. DOI

Křupka M., Vlčková J., Holý O. Vaccination. Palacky University Olomouc; Olomouc, Czech Republic: 2020.

Šejda J., Vaništa J., Doutlík S. Measles. Avicenum; Praha, Czech Republic: 1983. 152p

Trmal J., Limberková R. Report on a measles epidemic in the Ústí nad Labem Region. Epidemiol. Mikrobiol. Imunol. 2015;64:139–145. (In Czech) PubMed

Manďáková M.Z., Martinková M.I., Petroušová M.L., Ph D., Lexová M.P., Limberková M.R., Košťálová M.J., Kynčl M.J. Measles—Current epidemiological situation and clinical experience. Med. Praxi. 2017;14:234–237. doi: 10.36290/med.2017.045. (In Czech) DOI

Permar S.R., Griffin D.E., Letvin N.L. Immune containment and consequences of measles virus infection in healthy and immunocompromised individuals. Clin. Vaccine Immunol. 2006;13:437–443. doi: 10.1128/CVI.13.4.437-443.2006. PubMed DOI PMC

Griffin D.E. The immune response in measles: Virus control, clearance and protective immunity. Viruses. 2016;8:282. doi: 10.3390/v8100282. PubMed DOI PMC

Cohen B.J., Audet S., Andrews N., Beeler J. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine. 2007;26:59–66. doi: 10.1016/j.vaccine.2007.10.046. PubMed DOI

Štěpánek L., Nakládalová M., Boriková A., Horáková D., Štěpánek L. Measles immunity in a Czech tertiary care hospital. Vaccine. 2020;38:2889–2892. doi: 10.1016/j.vaccine.2020.02.067. PubMed DOI

World Health Organization . Global Measles & Rubella Strategic Plan. World Health Organization; Geneva, Switzerland: 2012. pp. 1–44.

Mrázová M., Šmelhausová M., Šestáková Z., Švandová E., Beneš Č. The 2001 serological survey in the Czech Republic—Mumps. Cent. Eur. J. Public Health. 2003;11:S36–S41. PubMed

Tomášková H., Zelená H., Kloudová A., Tomášek I. Serological survey of measles immunity in the Czech Republic, 2013. Cent. Eur. J. Public Health. 2018;26:22–27. doi: 10.21101/cejph.a5251. PubMed DOI

Smetana J., Chlibek R., Hanovcova I., Sosovickova R., Smetanova L., Gal P., Dite P. Decreasing seroprevalence of measles antibodies after vaccination—Possible gap in measles protection in adults in the Czech Republic. PLoS ONE. 2017;12:e0170257. doi: 10.1371/journal.pone.0170257. PubMed DOI PMC

Fleischmannová J., Šimečková E. Seroprevalence of IgG antibodies against measles in employees of the Hospital Strakonice. Epidemiol. Mikrobiol. Imunol. 2020;69:121–126. PubMed

Malinová J., Petráš M., Čelko A.M. A serosurvey identifying vulnerability to measles in health care workers. A hospital-based prospective seroprevalence study. Int. J. Environ. Res. Public Health. 2020;17:4219. doi: 10.3390/ijerph17124219. PubMed DOI PMC

Chen R.T., Markowitz L.E., Albrecht P., Stewart J.A., Mofenson L.M., Orenstein W.A., Orenstein W.A. Measles antibody: Reevaluation of protective titers. J. Infect. Dis. 1990;162:1036–1042. doi: 10.1093/infdis/162.5.1036. PubMed DOI

Dine M.S., Hutchins S.S., Thomas A., Williams I., Bellini W.J., Redd S.C. Persistence of Vaccine-Induced Antibody to Measles 26-33 Years after Vaccination. J. Infect. Dis. 2004;189:123–130. doi: 10.1086/380308. PubMed DOI

LeBaron C.W., Beeler J., Sullivan B.J., Forghani B., Bi D., Beck C., Audet S., Gargiullo P. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch. Pediatr. Adolesc. Med. 2007;161:294–301. doi: 10.1001/archpedi.161.3.294. PubMed DOI

Latner D.R., Sowers S.B., Anthony K., Colley H., Badeau C., Coates J., Wong P., Fakile Y., Interiano C., Pannell K.B., et al. Qualitative variation among commercial immunoassays for detection of measles-specific IgG. J. Clin. Microbiol. 2020;58:e00265-20. doi: 10.1128/JCM.00265-20. PubMed DOI PMC

Albrecht P., Ennis F.A., Saltzman E.J., Krugman S. Persistence of maternal antibody in infants beyond 12 months: Mechanism of measles vaccine failure. J. Pediatr. 1977;91:715–718. doi: 10.1016/S0022-3476(77)81021-4. PubMed DOI

Mok D.Z.L., Chan K.R. The effects of pre-existing antibodies on live-attenuated viral vaccines. Viruses. 2020;12:520. doi: 10.3390/v12050520. PubMed DOI PMC

Fiebelkorn A.P., Coleman L.A., Belongia E.A., Freeman S.K., York D., Bi D., Kulkarni A., Audet S., Mercader S., McGrew M., et al. Measles virus neutralizing antibody response, cell-mediated immunity, and immunoglobulin G antibody avidity before and after receipt of a third dose of measles, mumps, and rubella vaccine in young adults. J. Infect. Dis. 2016;213:1115–1123. doi: 10.1093/infdis/jiv555. PubMed DOI PMC

Van Binnendijk R.S., Poelen M.C.M., van Amerongen G., de Vries P., Osterhaus A.D.M.E. Protective Immunity in Macaques Vaccinated with Live Attenuated, Recombinant, and Subunit Measles Vaccines in the Presence of Passively Acquired Antibodies. J. Infect. Dis. 1997;175:524–532. doi: 10.1093/infdis/175.3.524. PubMed DOI